Cypress Capital Group Moderna, Inc. Transaction History

Cypress Capital Group

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 26, 2023	BUY	$118.5 - $160.53 $2,725 - $3,692	23 Added 0.78%	2,988 $363,000
Q1 2023 May 04, 2023	BUY	$135.66 - $197.02 $24,961 - $36,251	184 Added 6.62%	2,965 $455,000
Q4 2022 Feb 14, 2023	BUY	$118.38 - $210.04 $72,448 - $128,544	612 Added 28.22%	2,781 $499,000
Q3 2022 Nov 04, 2022	SELL	$118.07 - $194.18 $5,549 - $9,126	-47 Reduced 2.12%	2,169 $257,000
Q2 2022 Jul 26, 2022	BUY	$117.13 - $176.59 $54,231 - $81,761	463 Added 26.41%	2,216 $317,000
Q1 2022 May 16, 2022	BUY	$126.46 - $235.05 $92,568 - $172,056	732 Added 71.69%	1,753 $304,000
Q4 2021 Feb 15, 2022	SELL	$225.82 - $368.51 $228,078 - $372,195	-1,010 Reduced 49.73%	1,021 $259,000
Q3 2021 Oct 12, 2021	BUY	$221.9 - $484.47 $91,200 - $199,117	411 Added 25.37%	2,031 $782,000
Q2 2021 Jul 13, 2021	SELL	$129.91 - $234.98 $13,250 - $23,967	-102 Reduced 5.92%	1,620 $380,000
Q1 2021 Apr 14, 2021	SELL	$109.18 - $185.98 $90,619 - $154,363	-830 Reduced 32.52%	1,722 $226,000
Q4 2020 Jan 12, 2021	BUY	$65.74 - $169.86 $167,768 - $433,482	2,552 New	2,552 $267,000

954

241M

10.6M

18.7M

Ticker MRNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 391,200,000
Market Cap $14.4B
Description
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, resp...

Get notified when there are updates to the investment portfolio of Cypress Capital Group, based on Form 13F filings with the SEC.

Stay updated on Cypress Capital Group with notifications on news.